Your browser doesn't support javascript.
loading
The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer.
Zhao, Han-Xue; Xia, Chun-Xia; Yin, Hong-Xia; Guo, Ning; Zhu, Qiang.
Afiliación
  • Zhao HX; Department of Diagnostic Ultrasound, Beijing Tongren Hospital, Capital Medical University, Dong-Jiao-Min-Xiang, Dong Cheng District, Beijing 100730, PR China. Electronic address: zhaohx861@163.com.
Eur J Radiol ; 82(11): e641-7, 2013 Nov.
Article en En | MEDLINE | ID: mdl-23916578
ABSTRACT

OBJECTIVES:

To evaluate the role of contrast-enhanced transrectal ultrasonography (CE-TRUS) for detecting prostate carcinoma.

METHODS:

Sixty-five patients with elevated serum prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE) were assessed using transrectal ultrasound (TRUS) and CE-TRUS. In all the patients, CE-TRUS was performed with intravenous injection of contrast agent (SonoVue, 2.4 ml) before biopsy. The cancer detection rates of the two techniques were compared. False-positive and false-negative findings related to CE-TRUS were analyzed in comparison to the pathological results of biopsy or radical prostatectomy. The targeted biopsy to abnormal CE-TRUS areas was also compared to systematic biopsy.

RESULTS:

Prostate cancer was detected in 29 of the 65 patients. CE-TRUS showed rapid focal enhancement or asymmetric vessels of peripheral zones in 28 patients; 23 of them had prostate cancer. CE-TRUS had 79.3% sensitivity, compared to 65.5% of TRUS (P<0.05). There were five false-positive and six false-negative findings from CE-TRUS. Benign prostate hyperplasia, and acute and chronic prostatitis were important causes related to the false-positive results of CE-TRUS. Prostate cancer originating from the transition zone or peripheral zone with lower PSA levels, small-size foci, and moderately or well-differentiated tumor was missed by CE-TRUS. The cancer detection rate of targeted biopsy (75%, 33/44 cores) was significantly higher than one of systematic biopsy (48.2%, 162/336) in those 28 cases (P<0.05). In addition, no significant correlation was found between the cancer detection rate with CE-TRUS and serum PSA levels.

CONCLUSION:

CE-TRUS may improve the detection rate of prostate cancer through targeted biopsy of contrast-enhanced abnormalities. Our findings indicate that systematic biopsies should not be eliminated on the basis of false-positive and false-negative findings related to CE-TRUS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fosfolípidos / Neoplasias de la Próstata / Hexafluoruro de Azufre / Ultrasonografía Tipo de estudio: Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Eur J Radiol Año: 2013 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fosfolípidos / Neoplasias de la Próstata / Hexafluoruro de Azufre / Ultrasonografía Tipo de estudio: Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Eur J Radiol Año: 2013 Tipo del documento: Article